Evidence map›Paper›PMID 41950100›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer.

Fangdie Ye, Xuedan Han, Weijian Li, Lei Huang, Ziang Chen, Yu Lu, Hang Huang, Haowen Jiang, Lufeng Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fangdie Ye *Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Xuedan Han *Department of Biopharmaceuticals, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province 211198, China.
Weijian Li *Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Lei HuangDepartment of Molecular Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA 01605.ORCID 0000-0002-0568-0645
Ziang ChenDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Yu LuDepartment of Biopharmaceuticals, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province 211198, China.
Hang HuangDepartment of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou City 325000, China.ORCID 0009-0008-5029-9190
Haowen JiangDepartment of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.
Lufeng ZhengDepartment of Biopharmaceuticals, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu Province 211198, China.ORCID 0000-0002-2183-4974

Funding

MOST | National Natural Science Foundation of China (NSFC) 82173842MOST | National Natural Science Foundation of China (NSFC) 82473955
6 · The paper itself

Abstract

Bladder cancer remains a significant therapeutic challenge due to its marked heterogeneity and capacity for immune evasion. Here, we employ spatial metabolomics and spatial transcriptomics to systematically characterize and visualize the metabolic and transcriptional landscapes of bladder cancer. Our findings identify distinct metabolic and transcriptional profiles across different tumor regions, highlighting heterogeneity and immune-associated metabolic reprogramming in BLCA. Further investigation identifies zinc finger protein 36 (ZFP36) as a potential immunotherapeutic target. Utilizing

Indexed as

TristetraprolinUrinary Bladder NeoplasmsAnimalsGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingMetabolomicsMiceMice, KnockoutMultiomicsSpatial TranscriptomicsT-LymphocytesTristetraprolinZFP36 protein, humanZfp36 protein, mousebladder cancerimmune metabolic reprogrammingspatial metabolomicsspatial transcriptomicsZFP36

Identifiers

PMID41950100
PMCPMC13079991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.